StageZero Life Sciences: Top 10 Undervalued Medical Diagnostics & Research Industry Stocks (SZLS)
StageZero Life Sciences is now ranked among the top 10 undervalued stocks in the Medical Diagnostics & Research industry on the Toronto Stock Exchange or TSX Venture Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below).
Medical Diagnostics & Research: Companies that provide laboratory testing services through imaging and other diagnostic services to the medical industry. Stocks in this category are held primarily for capital appreciation.
|Symbol||Name||Close Price ($)||Valuation ($)||Difference||Average Vol (30D)||Market Cap ($M)||Yield (%)||P/E Ratio|
|MBI-H-X||Many Bright Ideas||0.03||0.03||0.01|
|SZLS-T||StageZero Life Sciences||0.07||0.17||0.11|
More about StageZero Life Sciences
All data provided as-at market close January 19, 2023. The list is sorted by stocks with the greatest percentage difference between valuation and price. StageZero Life Sciences GeneNews Ltd is focused on developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and personalized health management, with a primary focus on cancer-related indications. StageZero Life Sciences is listed under SZLS on the Toronto Stock Exchange.
StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs. StockCalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. StockCalc's Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including: Discounted Cash Flow (DCF), Price & Other Comparables, Multiples, Adjusted Book Value (ABV) and Analyst Consensus
Artificial intelligence at Report on Business
Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.